Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A | P37288 | 1/20 | 0.59 |
| ▸ | NPY5R | Q15761 | 11/20 | 0.55 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4987131 | 0.88 | AVPR1A (0.56) | AVPR1ANPY5RHSD11B1CYP2D6GAA | |
| SCHEMBL3839680 | 0.86 | P2RX7 (0.50) | AVPR1ANPY5RP2RX7 | |
| SCHEMBL3836672 | 0.85 | AVPR1A (0.63) | AVPR1ANPY5RHSD11B1CYP2D6SIGMAR1 | |
| SCHEMBL3837159 | 0.85 | AVPR1A (0.55) | AVPR1ANPY5RHSD11B1CYP2D6SIGMAR1 | |
| SCHEMBL3841668 | 0.84 | HRH3 (0.49) | AVPR1ANPY5RHRH3P2RX7 | |
| SCHEMBL3836464 | 0.83 | HRH3 (0.49) | AVPR1ANPY5RHRH3P2RX7 | |
| SCHEMBL3842034 | 0.81 | AVPR1A (0.46) | AVPR1ANPY5RHRH3GAAP2RX7 | |
| SCHEMBL3845345 | 0.79 | AVPR1A (0.57) | AVPR1ANPY5RHSD11B1CYP2D6SIGMAR1 | |
| SCHEMBL3837956 | 0.78 | AVPR1A (0.53) | AVPR1ANPY5RHSD11B1CYP2D6SIGMAR1 | |
| SCHEMBL4527534 | 0.76 | HSD11B1 (0.53) | AVPR1ANPY5RHSD11B1CYP2D6HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8084609-B2 | Vasopressin receptor (V1a) antagonists, treatment of anxiety and depressive disorders and other diseases | HOFFMAN-LA ROCHE INC. (US) | 2011-12-27 | — | — | US | claimed |
| US-20080153861-A1 | SPIROPIPERIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-26 | — | — | US | claimed |
| EP-2535329-A2 | Spiro-piperidine derivatives | F. Hoffmann-La Roche AG (CH) | 2012-12-19 | — | — | EP | disclosed |
| EP-2535329-A2 | Spiro-piperidine derivatives | F. Hoffmann-La Roche AG (CH) | 2012-12-19 | — | — | EP | disclosed |
| US-8084609-B2 | Vasopressin receptor (V1a) antagonists, treatment of anxiety and depressive disorders and other diseases | HOFFMAN-LA ROCHE INC. (US) | 2011-12-27 | — | — | US | disclosed |
| US-8084609-B2 | Vasopressin receptor (V1a) antagonists, treatment of anxiety and depressive disorders and other diseases | HOFFMAN-LA ROCHE INC. (US) | 2011-12-27 | — | — | US | disclosed |
| US-8084609-B2 | Vasopressin receptor (V1a) antagonists, treatment of anxiety and depressive disorders and other diseases | HOFFMAN-LA ROCHE INC. (US) | 2011-12-27 | — | — | US | disclosed |
| EP-2097376-A2 | SPIRO-PIPERIDINE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2009-09-09 | — | — | EP | disclosed |
| WO-2008077810-A2 | SPIRO-PIPERIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-07-03 | — | — | WO | disclosed |
| WO-2008077810-A2 | SPIRO-PIPERIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-07-03 | — | — | WO | disclosed |
| US-20080153861-A1 | SPIROPIPERIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-26 | — | — | US | disclosed |
| US-20080153861-A1 | SPIROPIPERIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-26 | — | — | US | disclosed |
| US-20080153861-A1 | SPIROPIPERIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-26 | — | — | US | disclosed |
| US-20080153862-A1 | SPIROPIPERIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-26 | — | — | US | disclosed |
| US-20080153862-A1 | SPIROPIPERIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-26 | — | — | US | disclosed |
| US-20080153862-A1 | SPIROPIPERIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-26 | — | — | US | disclosed |
| US-20080153863-A1 | SPIROPIPERIDINE DERIVATIVES | HOFFMAN-LA ROCHE INC. | 2008-06-26 | — | — | US | disclosed |
| US-20080153863-A1 | SPIROPIPERIDINE DERIVATIVES | HOFFMAN-LA ROCHE INC. | 2008-06-26 | — | — | US | disclosed |
| US-20080153863-A1 | SPIROPIPERIDINE DERIVATIVES | HOFFMAN-LA ROCHE INC. | 2008-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153863-A1 | SPIROPIPERIDINE DERIVATIVES | AVPR1A, AVPR1B, AVPR2 | AVPR1A 1/4885NPY5R 22/4885HSD11B1 1341/4885 |
| US-20080153861-A1 | SPIROPIPERIDINE DERIVATIVES | AVPR1A, AVPR1B, AVPR2 | AVPR1A 1/4885NPY5R 22/4885HSD11B1 1341/4885 |
| US-20080153862-A1 | SPIROPIPERIDINE DERIVATIVES | AVPR1A, AVPR1B, AVPR2 | AVPR1A 1/4885NPY5R 22/4885HSD11B1 1341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.